Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of ITI-1284 in Generalized Anxiety Disorder
NCT07807865Phase 3Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Sep 2026
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deulumateperone in generalized anxiety disorder (GAD), sponsored by Intra-Cellular Therapies. Primary endpoint: Number of Participants with Adverse Events at 52 weeks. Started Sep 2026; status: recruiting.
02
Drugs
deulumateperone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07807865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807865.